Our study demonstrated that 17% of patients with primary or secondary endocrine-resistant breast cancer harbored germline pathogenic variants of BRCA1, BRCA2, or PTEN. TP53 gene mutations were affected by primary endocrine resistance and poor overall survival. Here, TP53 is linked to breast cancer.